Founded in 1940, our objective is to avoid and cure diabetes and to improve the lives of most people suffering from diabetes. WHEN: November 2, 2009 WHY: With nearly 24 million kids and adults afflicted with the disease in the U.S. And an additional 57 million at risk for type 2 diabetes, diabetes has reached epidemic proportions. If current developments continue, one out of three children shall encounter a future with diabetes. HOW: To allow your viewers/listeners/readers find out about American Diabetes Month and the Quit Diabetes movement.It offers us additional confidence as we move into the next Phase 2a research and we believe it represents a key de-risking event for growing our pipeline of RNAi therapeutics predicated on the DPC platform, stated Christopher Anzalone, Ph.D., President and CEO. The Phase 1 trial was designed to characterize the protection profile of ARC-520 across a variety of doses and assess pharmacokinetics. It really is a single-center, randomized, double-blind, placebo-controlled, solitary dose-escalation, first-in-human study of ARC-520 administered intravenously to healthy adult volunteers.